Genta, Inc. acquired Salus Therapeutics, Inc. a company that specializes in the identification and development of drugs that are based on DNA or RNA, in 2003.

Genta is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The company's research platform is anchored by two major programs that center on DNA/RNA-based medicines and small molecules. Genasense is the company's lead compound from its DNA/RNA Medicines program and is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite, which the company intends to market for the treatment of cancer-related hypercalcemia that is resistant to hydration.